CORONARY ARTERY BYPASS GRAFTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Coronary Artery Bypass Grafting Market Size and Trends

Global coronary artery bypass grafting market is estimated to be valued at USD 14.02 Bn in 2024 and is expected to reach USD 26.15 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2024 to 2031.

To learn more about this report, request sample copy

Rising burden of cardiovascular diseases and increasing adoption of minimally invasive procedures can boost demand for coronary artery bypass grafting. Moreover, growing geriatric population prone to chronic heart conditions and advancements in bypass grafting technologies can drive the market growth. However, high treatment costs associated with CABG and availability of alternative treatment options can hamper the market growth during the forecast period.

Rising prevalence of cardiovascular diseases

Rising prevalence of cardiovascular diseases across the world can drive the global coronary artery bypass grafting market growth. Coronary artery disease is one of the leading causes of mortality and morbidity globally. It has been estimated that over 17 million people die annually from cardiovascular diseases. The major risks factors for coronary artery disease include diabetes, tobacco use, unhealthy diet, physical inactivity, excessive alcohol consumption and obesity. Many countries around the world are witnessing increase in prevalence of these risk factors in their populations due  to rapid urbanization, aging populations and changes in lifestyle habits. For example, according to the data from World Health Organization, over 1.9 billion adults aged 18 years and older were overweight in 2016, out of which, over 650 million adults were obese. Furthermore, the number of diabetics worldwide had increased from 108 million in 1980 to 422 million in 2014. Unless effective preventive measures are taken, these factors will boost rates of cardiovascular diseases.  Coronary artery bypass grafting is one of the main surgical procedures in the management of coronary artery disease, and this is expected to drive the market growth.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Improving reimbursement scenario for CABG procedures

Growing medical reimbursement and insurance coverage for cardiovascular procedures like coronary artery bypass grafting can drive the market growth. Traditionally, exorbitant costs of cardiac surgery made it unaffordable for many people. However, favorable medical reimbursement policies introduced by public and private payers are enhancing the accessibility of CABG. For example, government-sponsored insurance schemes in many countries now cover CABG procedures, subject to certain conditions. Private medical insurers are also expanding insurance plans that offer CABG coverage. Such third-party coverage has resulted in more patients opting for the procedure who otherwise would hesitate due to financial constraints. Cardiac societies and advocacy groups too are lobbying for higher reimbursements from insurance firms. Growing reimbursement rates are encouraging more healthcare providers to offer CABG services, thus, widening treatment availability. Reimbursements are also supporting investments in advanced technologies and infrastructure expansion by CABG service providers.

Key Takeaways from  Analyst:

Global coronary artery bypass grafting market growth is driven by rising geriatric population and increasing prevalence of cardiovascular diseases. The number of people suffering from conditions that require CABG procedures, such as coronary artery disease, is growing rapidly across major regions. This can boost demand for CABG services in the near future. North America currently dominates the market, owing to region's superior healthcare infrastructure and high accessibility to treatment options. However, Asia Pacific is likely to emerge as the fastest growing regional market due to advancements in medical technologies and growing awareness.

Although the number of CABG surgeries is increasing, however, rising adoption of non-surgical treatments can hamper the market growth. The availability of alternative treatments like percutaneous coronary intervention (PCI) can hamper the market growth. However, traditional CABG still remains the gold standard for multi-vessel disease. Ongoing research into minimally invasive CABG techniques and robot-assisted surgeries that could help reduce recovery time and related risks can offer growth opportunities. New product launches catering to high-risk patient groups can also drive the market growth over the forecast period.

Market Challenges: High cost of coronary artery bypass grafting procedures

The high cost of coronary artery bypass grafting (CABG) procedures can hamper the growth of global Coronary Artery Bypass Grafting Market. CABG is a major cardiac surgery that requires considerable hospital stay and has high costs associated with operation theater charges, equipment, postoperative care, medicines and extended stay in the ICU. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2022, the average total hospital costs for CABG surgery in the U.S. range from US$ 80,000 to over US$ 150,000, depending on the complications involved and the facilities where the surgery is performed. These elevated costs pose a serious financial burden on patients and make CABG mostly unaffordable for the common masses, especially those living in developing nations with low per capita incomes. For many people, cardiac conditions are managed through alternate treatments and drug therapies despite being less effective compared to revascularization through CABG. According to a study published in 2021 by World Health Organization (WHO), around 57% of cardiovascular patients in low and lower-middle income countries opt out of CABG due to financial constraints compared to only 17% patients in high income countries. The costs involved also discourage private and public health insurers from including CABG in their insurance coverage in many emerging economies.  

Market Opportunities: Development of innovative disposable and integrated device technologies

The development of innovative disposable and integrated device technologies can offer major opportunity for growth of global coronary artery bypass grafting market. Coronary artery bypass grafting or CABG is a widely performed procedure to treat coronary artery disease, one of the leading causes of mortality worldwide. While traditional CABG has been effective, new disposable and integrated device technologies have the potential to significantly improve outcomes and increase access to care. Some of the innovative technologies being developed could make the CABG procedure less invasive and reduce complications. For example, devices that integrate tissue harvesting, preparation and placement into a single-use cartridge or cassette. Such integrated devices streamline the workflow for surgeons and reduce the risk of infections from reuse of instruments. Similarly, fully disposable systems for tasks like vessel harvesting and graft optimization eliminate the need for cleaning and sterilization of equipment between procedures. This not only improves safety but allows for better inventory management and cost control for healthcare facilities. Fully disposable or rapidly deployable device suites could also enable the conduct of CABG procedures in ambulatory surgical centers or even in field hospitals. As per estimates by the World Bank, non-communicable diseases was projected to cost low- and middle-income countries US$ 7 trillion in economic losses from 2011 to 2025. Innovative technologies that optimize the CABG procedure and expand access to cardiac care in more points of service have potential to significantly reduce this growing economic burden of cardiovascular diseases in developing nations.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

By Technology- Ease of procedure and standardization can boost on-pump CABG adoption

In terms of technology, on-pump CABG segment is expected to contribute the highest market share of 45.1% in 2024, owing to its relative ease of procedure as compared to off-pump CABG. The on-pump procedure uses a heart-lung machine to circulate the patient's blood and take over the function of the heart and lungs, allowing the surgeon to work on a still, bloodless field. This provides optimal surgical access and visibility for grafting, as the heart is temporarily stopped from beating. The use of cardiopulmonary bypass also enables complex multi-vessel bypass surgeries to be performed with reproducible outcomes. Standardization of the on-pump procedure over decades of practice worldwide has led to refinement of surgical techniques. Clear steps and workflows during surgery reduce variability between surgeons and institutions. This standardization and the controlled surgical environment afforded by cardioplegia and bypass have allowed on-pump CABG to become the most common and widely adopted CABG procedure globally. Hospitals and cardiac centers are well-equipped with the infrastructure, expertise and experience to perform on-pump CABG routinely. While off-pump CABG aims to avoid potential complications of cardiopulmonary bypass, it remains technically challenging due to the need for improved stabilization devices and a beating, blood-filled heart. Not all cases and patients are amenable to off-pump bypass. Thus, on-pump CABG segment dominates due to its benefits of established ease of use, consistency and operator familiarity as compared to evolving off-pump methods.

By Product- Grafts are indispensable for reconstituting coronary blood flow

In terms of product, grafts segment is expected to contribute the highest market share of 42.6% in 2024, due to being the key product indispensable for actually performing the bypass surgery. Several types of grafts are used to reroute blood flow around blocked arteries and restore adequate circulation to the heart muscle. The internal mammary artery and saphenous vein are most commonly used as graft conduits due to their resilience and ability to remain patent over the long term. A crucial aspect of CABG surgery is properly harvesting and preparing graft vessels to be sized and attached appropriately based on the target coronary arteries. A range of grafts with small, delicate sizes are needed to precisely re-vascularize different territories of the heart. Given surgeries often require multiple bypasses using sequential or composite grafts, adequate conduit material is indispensable. As the very core component conducting blood around blockages, high quality graft products ensure effective, durable bypass conduits. Continuous innovation aims to improve graft handling qualities and long-term patency. Development of alternative grafts using other vessels or synthetic materials also expands options for patients with inadequate autologous tissue. The crucial role of graft products in enabling successful CABG can drive the segment growth.

By End User- Hospitals are preferred settings for CABG due to surgical expertise and resources

In terms of end user, hospitals segment is expected to contribute the highest market share of  37.12 % in 2024, as these remain the preferred settings for CABG procedures due to availability of multidisciplinary surgical teams, specialized cardiac facilities and infrastructure. Complex CABG surgery requires a coordinated effort from cardiac surgeons, anesthetists, perfusionists, cardiac nursing and technical staff. It also necessitates dedicated cardiac operating rooms, intensive care units and equipment like heart-lung machines and specialty sutures/devices. Most hospitals have established programs performing hundreds of CABG cases annually, maintaining the surgical expertise, experience and rapid response times important for emergent cases. Cardiac surgeons are often hospital-based and large volume centers can participate in clinical trials and new innovation more readily. Hospitals also offer holistic care for in-patients from pre-op assessment and education to post-op rehab, reducing burden on patients and families compared to non-hospital settings. While select outpatient centers have expanded capacity, relatively stable hospital infrastructure and surgical resources continue catering to complex CABG.

Regional Insights

To learn more about this report, request sample copy

North America dominates the global coronary artery bypass grafting market with an estimated market share of 39.3% in 2024. With a highly developed healthcare system and growing prevalence of cardiovascular diseases, the U.S. accounts for the largest share within the region. Favorable reimbursement policies for cardiac procedures have encouraged the adoption of CABG. Moreover, presence of leading medical device manufacturers influences clinical practice and innovation within the U.S. Hospitals in the U.S. are well-equipped to perform CABG procedures and trained cardiothoracic surgeons are readily available nationwide.

Universal healthcare coverage enables broader access to treatment. Guidelines recommend CABG as the standard of care for select patient groups, driving the market growth. North America faces challenges of an aging population and rising obesity rates that increase the burden of heart disease over the long term.

Asia Pacific is poised to emerge as the fastest growing regional market for coronary artery bypass grafting. Economies like India and China are industrializing rapidly and experiencing growth in lifestyle diseases. While rudimentary cardiac care exists, cardiovascular specialists are actively working to spread awareness and enhance capacity. Governments provide some level of healthcare coverage that boosts demand for CABG from an expanding middle class. Foreign investment and medical tourism additionally stimulate the supply side infrastructure in Asia Pacific. The combination of unmet needs, improving standards and supportive policy frameworks can propel this region to become a global hotspot.

Market Report Scope

Coronary Artery Bypass Grafting Industry News

• In April 2024,The Society of Thoracic Surgeons (STS) introduced new risk calculators for isolated tricuspid valve repair and replacement, surgical aortic valve replacement (SAVR) following prior transcatheter aortic valve replacement (TAVR), and multi-valve surgeries with or without coronary artery bypass grafting (CABG)
• In August 2022, Medtronic plc, a medical device company, announced its acquisition of Affera, Inc., enhancing its cardiac ablation portfolio with its first comprehensive cardiac mapping and navigation platform. This new platform integrates a distinctive combination of diagnostic tools, focal pulsed field ablation, and radiofrequency ablation solutions.
• In January 2022, Humacyte, Inc. reported positive results from a preclinical study of its small-diameter Human Acellular Vessel (HAV) used in coronary artery bypass grafting (CABG). The HAV maintained patency and showed effective host-cell remodeling in a non-human primate model. CABG, performed around 400,000 times yearly in the U.S., typically uses saphenous vein grafts, which have a 30% failure rate within a year.

*Definition: Global Coronary Artery Bypass Grafting Market involves surgical procedures where blood vessels or veins from other parts of the body are used to bypass narrow or blocked coronary arteries and improve blood flow to the heart. The market covers medical devices used for coronary artery bypass grafting such as vein grafts, arterial grafts, graft preparation devices, positioning and stabilization devices, and heart-lung machines. The global market also encompasses associated technologies and services for coronary artery bypass grafting procedures.

Market Segmentation

•  Technology Insights (Revenue, USD Bn, 2019 - 2031)
  • Off-pump CABG
  • On-pump CABG
  • Others
•  Product Insights (Revenue, USD Bn, 2019 - 2031)
  • Grafts
    • Saphenous vein grafts
    • Internal thoracic artery grafts
    • Other grafts
  • Retractors
  • Heart positioners    
  • Tissue stabilizers
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospitals
  • Cardiology Clinics
  • Ambulatory surgical centers
  • Academic & Research institute
  • Other
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott Laboratories
  • Medtronic
  • Boston Scientific Corporation
  • LivaNova PLC
  • Edwards Lifesciences Corporation
  • Maquet Holding B.V. & Co. KG
  • TERUMO CORPORATION
  • Guidant
  • Vitalitec
  • Novadaq
  • KARL STORZ
  • Ethicon US, LLC (Johnson & Johnson)
  • NeoGraft Technologies, Inc.
  • Genesee Biomedical Inc.
  • Hancock Jaffe Laboratories, Inc.
  • VasoPrep Surgical
  • Dextera Surgical Inc.
  • Neograft Inc.